FDA Enforcement Discretion Hearing

Amanda Kabage, our Research Program Manager, spoke at a public FDA hearing to discuss the clinical evidence for safety and efficacy of FMT treatment for recurrent C. difficile patients under the FDA’s enforcement discretion policy. View Here.